What Happened?
Bedford, TX-based Nanoscope-Therapeutics Appointed Aaron Osborne as Chief Development Officer
About the Company
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
About the Person
Aaron Osborne is Chief Development Officer at Nanoscope Therapeutics. Previously, Aaron held various senior HR leadership roles in the industry.
Info Source
News
Short Profile